Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Dow, S&P 500, and Nasdaq futures are falling in premarket trading Thursday as the stock market digests CPI inflation data and braces for Trump's response to Canada and EU tariffs.

Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...